|Day Low/High||43.47 / 43.90|
|52 Wk Low/High||36.00 / 46.47|
Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.
Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.
Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of six tranches of notes: $300,000,000 aggregate principal amount of floating rate notes due 2023 $1,000,000,000 aggregate principal amount of 3.
Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label...
Markets were higher Tuesday after starting Tuesday's session off in the green.
The S&P 500 and Nasdaq set record highs as stocks rose Monday after the U.S. and Mexico reached a tentative trade agreement.
Pfizer Inc. (NYSE:PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed tafamidis significantly reduced the hierarchical combination of both all-cause mortality and frequency of...
A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.
Jim Cramer explains the art and science of technical analysis. Plus, he has next week's game plan.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc.
Traders should raise sell stops to just above $40 from below $35.50
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.
Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.
Retail earnings are in full swing with results from Walmart and J.C. Penney. All eyes still on the cannabis space. Big day for tool king Stanley Black & Decker.
Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.
Time to brace for a summer pullback?
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with...
Major indexes gave ground in the final minutes of trade, but managed to stay in positive territory at the close.
Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.
Global stocks continued to edge lower Tuesday, as tech sector weakness bled into markets in Asia following last night's sell off on Wall Street, putting even more pressure on today's third quarter earnings report from Apple at the close of trading today.
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS (2).
U.S. stock futures are rising slightly on Tuesday ahead of earnings from Apple and as a two-day meeting of the Federal Reserve gets set to begin.
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™, 1 a biosimilar to Herceptin ®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing...
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.